Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...
How is Orna using RNA to create therapeutics for cancer? Using circular RNA, we’ve developed a platform we call isCAR™ for the in vivo delivery of CARs to immune cells. RNA is transient, but circular ...
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...
Intellia Therapeutics is pioneering in vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results